Skip to main content
Caplight Logo









ProxyBio

ProxyBio

Private
Tucson, ArizonaHealthcare & Life Scienceshttps://proxybio.com/

Last Round

Seed

May 26, 2026

Total Funding Raised

$3.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

ProxyBio, Inc. is a biotechnology company that has developed a stem cell-derived 3D culture system designed for research and therapeutic development in complex diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS, Usage-Based SaaS

AI Layer

Application

Keywords

patient-derived organoidsAI drug discoverydrug discovery platformorganoid screeninganimal testing alternativetumoroidshigh-throughput screeningHTSpersonalized medicinepreclinical safety assessmentsingle-cell analysiscompanion diagnosticsbiological digital twinpatient avatarspatient stratificationbiomarker identification

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ProxyBio Comparables

Compare ProxyBio with similar companies based on industry and business-model similarity.

ProxyBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vivodyne
81%
KYAN Technologies
79%
Signet Therapeutics
76%

ProxyBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 26, 2026

Key People

Founding team and executive leadership

Curtis Thorne

Chief Executive Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 26, 2026

    Raised $4M in seed funding.

ProxyBio Filings

Explore SEC and related filing metadata, where available.

ProxyBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ProxyBio's valuation, stock price, and market status.

Is ProxyBio a public or private company?

ProxyBio is a private company.

What is the current stock price of ProxyBio?

ProxyBio is a private company with no public stock price. No recent secondary market data is available.

How much is ProxyBio worth (valuation)?

Valuation information for ProxyBio is not publicly available.

Can I buy ProxyBio stock?

ProxyBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ProxyBio's last funding round?

ProxyBio's most recent funding round was Seed on May 26, 2026.

Who are the main investors in ProxyBio?

Investor information for ProxyBio is not publicly disclosed.

Will ProxyBio IPO soon?

No public IPO plans have been announced for ProxyBio.

How can I track ProxyBio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ProxyBio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTucson, Arizona
Employee Range3
Year Founded2025
Last FundingMay 26, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?